Wilmington, DE, United States of America

Lixin Shao

This inventor holds 33 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in PI3K Inhibitors. Top assignees: Incyte Corporation, Incyte Holdings Corporation. Active years: 2014-2026.

USPTO Granted Patents = 33 (Patent Applications = 10)

% Patents Active = 93.9

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 12)

Average Co-Inventor Count = 6.4

ph-index = 12

Forward Citations = 506(Granted Patents)

Location History:

Newark, DE (US) (2014 - 2016)
Newark, DE (2016)
Wilmington, DE (US) (2017 - 2024)

Company Filing History:

Incyte Holdings Corporation

patents

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

PI3K Inhibitors

Aminopyrazine Derivatives

Heterocyclic Compounds

JAK Inhibitors

Spirocyclic Lactams

Tricyclic Heterocycles

Naphthyridinone Compounds

Tertiary Alcohols

Imidazo Compounds

Pyridine Compounds

Diol Compounds

BET Protein Inhibitors

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12516065 - Tertiary alcohols as PI3K-γ inhibitors (2026-01-06),

2. 12421197 - Aminopyrazine derivatives as PI3K-γ inhibitors (2025-09-23),

3. 12365668 - Aminopyrazine diol compounds as PI3K-y inhibitors (2025-07-22),

4. 12030885 - Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors (2024-07-09),

5. 12006320 - Heterocyclic derivatives as PI3K inhibitors (2024-06-11),

6. 11958861 - Spirocyclic lactams as JAK2 V617F inhibitors (2024-04-16),

7. 11952367 - Pyridine and pyridimine compounds as PI3K-gamma inhibitors (2024-04-09),

8. 11926630 - Tertiary alcohols as PI3K-γ inhibitors (2024-03-12),

9. 11926616 - Aminopyrazine diol compounds as PI3K-γ inhibitors (2024-03-12),

10. 11773102 - Heterocyclic compounds as PI3K-γ inhibitors (2023-10-03),

11. 11691971 - Naphthyridinone compounds as JAK2 V617F inhibitors (2023-07-04),

12. 11352340 - Pyridine and pyridimine compounds as PI3K-gamma inhibitors (2022-06-07),

13. 11306079 - 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors (2022-04-19),

14. 11225486 - Tertiary alcohols as PI3K-γ inhibitors (2022-01-18),

15. 11091491 - Heterocyclic compounds as PI3K-y inhibitors (2021-08-17),

Title: Lixin Shao: A Pioneering Innovator in Pharmaceutical Development

Introduction

Lixin Shao is a distinguished inventor based in Wilmington, Delaware, with an impressive portfolio of 30 patents. His groundbreaking work primarily focuses on the development of compounds that serve as inhibitors for critical biochemical pathways, particularly in the context of treating complex diseases.

Latest Patents

Among his latest patents are "Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors" and "Heterocyclic derivatives as PI3K inhibitors". These patents relate to innovative compounds that can be used to inhibit PI3K-γ, offering potential therapeutic applications for various disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Career Highlights

Lixin Shao has made significant strides in the pharmaceutical sector through his work with notable companies, including Incyte Corporation and Incyte Holdings Corporation. His expertise and contributions have considerably advanced drug development processes in combating serious diseases.

Collaborations

Throughout his career, Lixin has collaborated with numerous professionals, including his coworkers Stacey Shepard and Nikoo Falahatpisheh. Their combined expertise has played a crucial role in achieving the innovative outcomes for which Lixin is recognized.

Conclusion

Lixin Shao's contributions to the field of pharmaceuticals highlight his dedication to innovation and improving human health. With a solid patent portfolio and ongoing research, he continues to be a valuable asset in the quest for new therapeutic solutions.